We are live on ! Find out more
Julian Baker

Julian Baker Baker Bros. Advisors

AUM $21B Turnover 13.64%
1-Year Est. Return 107.69%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+6.87%
1 Year Est. Return
+107.69%
3 Year Est. Return
+551.08%
5 Year Est. Return
+837.56%
10 Year Est. Return
+4,965.51%
AUM
$9.5B
AUM Growth
+$55.8M
Cap. Flow
-$1.48B
Cap. Flow %
-15.48%
Top 10 Hldgs %
82.65%
Holding
142
New
10
Increased
13
Reduced
15
Closed
7
Avg Time Held
1.7 years
Top 10 Avg Time Held
1.8 years
Top 20 Avg Time Held
1.4 years

Sector Composition

Rank Sector Weight
1 Healthcare 86.04%
2 Miscellaneous 13.95%
3 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
INCY icon
1
Incyte
INCY
$24.3B
$1.88B 19.7%
23,498,697
+237
+0% +$18.4K
2013 Q2
12 quarters
SGEN
2
DELISTED
Seagen
SGEN
$1.75B 18.32%
43,238,967
+3,700
+0% +$141K
2013 Q2
12 quarters
ABBV icon
3
AbbVie
ABBV
$510B
$890M 9.33%
14,373,538
– –
2015 Q2
4 quarters
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$3.12B
$796M 8.34%
24,516,738
+302,900
+1% +$10.1M
2013 Q2
12 quarters
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$764M 8.01%
6,543,295
+696
+0% +$98.8K
2015 Q2
4 quarters
BMRN icon
6
BioMarin Pharmaceuticals
BMRN
$11.6B
$374M 3.92%
4,806,483
– –
2013 Q2
12 quarters
GHDX
7
DELISTED
Genomic Health
GHDX
$354M 3.71%
13,668,866
+9,034
+0.1% +$240K
2013 Q2
12 quarters
DBVT icon
8
DBV Technologies
DBVT
$618M
$180M 1.88%
550,956
– –
2014 Q4
6 quarters
ACOR
9
DELISTED
Acorda Therapeutics
ACOR
$93.4M 0.98%
30,509
– –
2014 Q1
9 quarters
CERS icon
10
Cerus
CERS
$402M
$84.6M 0.89%
13,553,275
– –
2013 Q2
12 quarters
ONCE
11
DELISTED
Spark Therapeutics
ONCE
$67.4M 0.71%
1,318,341
+55,959
+4% +$2.39M
2015 Q1
5 quarters
BLCM
12
DELISTED
Bellicum Pharmaceuticals
BLCM
$63.1M 0.66%
486,565
– –
2014 Q4
6 quarters
ONC icon
13
BeOne Medicines
ONC
$46.1B
$57M 0.6%
1,912,680
– –
2016 Q1
1 quarter
HRTX icon
14
Heron Therapeutics
HRTX
$53.2M
$51.6M 0.54%
2,857,250
-50,534
-2% -$987K
2014 Q1
9 quarters
NGNE icon
15
Neurogene
NGNE
$478M
$51.3M 0.54%
387,624
– –
2014 Q1
9 quarters
NVTA
16
DELISTED
Invitae
NVTA
$48.4M 0.51%
6,554,967
– –
2015 Q1
5 quarters
BCRX icon
17
BioCryst Pharmaceuticals
BCRX
$1.93B
$42.6M 0.45%
15,010,534
– –
2013 Q2
12 quarters
NBIX icon
18
Neurocrine Biosciences
NBIX
$16.5B
$40.7M 0.43%
895,422
– –
2014 Q1
9 quarters
ARAV
19
DELISTED
Aravive
ARAV
$30.1M 0.32%
453,900
-79,360
-15% -$4.51M
2014 Q2
8 quarters
AAAP icon
20
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$25.2M 0.26%
833,089
+218,056
+35% +$6.94M
2015 Q4
2 quarters
XNPT
21
DELISTED
XenoPort
XNPT
$24.5M 0.26%
3,475,672
– –
2013 Q2
12 quarters
ITCI icon
22
DELISTED
Intra-Cellular Therapies
ITCI
$23.6M 0.25%
609,166
– –
2015 Q1
5 quarters
SGMO icon
23
DELISTED
Sangamo Therapeutics
SGMO
$23.5M 0.25%
4,055,876
– –
2013 Q3
11 quarters
NTLA icon
24
Intellia Therapeutics
NTLA
$1.41B
$22.7M 0.24%
+1,062,120
New +$28.3M
2016 Q2
0 quarters
EXEL icon
25
Exelixis
EXEL
$16.8B
$20.2M 0.21%
2,580,000
– –
2016 Q1
1 quarter

Similar funds

Julian Baker's Q2 2016 Portfolio in Review

As of Q2 2016, Julian Baker held 142 positions worth $9.5B, up 0.59% from $9.48B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Julian Baker withdrew a net $1.48B in Q2 2016, closing 7 positions and reducing 15 holdings. Its most notable exit was Anacor Pharmaceuticals, an estimated $274M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 82% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Julian Baker opened a new position in Intellia Therapeutics worth $22.7M.

  • Julian Baker's largest Q2 2016 buy was Intellia Therapeutics: 1,062,120 shares worth $22.7M.
  • Julian Baker added most to Acadia Pharmaceuticals in Q2 2016, an estimated $10.1M increase.
  • Julian Baker's biggest Q2 2016 reduction was Mirati Therapeutics, cutting an estimated $15.9M.
  • Julian Baker fully exited Anacor Pharmaceuticals in Q2 2016, selling an estimated $274M.
  • Julian Baker's ten largest holdings make up 83% of its $9.5B portfolio in Q2 2016.
  • Julian Baker opened 10 new positions and closed 7 in Q2 2016.
  • Julian Baker's portfolio value rose 0.59% quarter-over-quarter to $9.5B.

Based on Baker Bros. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.